This is a GSBR-1290 news story, published by Yahoo Finance, that relates primarily to Brian Cheng news.
For more GSBR-1290 news, you can click here:
more GSBR-1290 newsFor more Brian Cheng news, you can click here:
more Brian Cheng newsFor more drug discoveries news, you can click here:
more drug discoveries newsFor more news from Yahoo Finance, you can click here:
more news from Yahoo FinanceOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
investors today. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest stocks news, year upside potential news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
Best StocksTipRanks
•79% Informative
Since 1950 , whenever the S&P 500 has gained at least 10% in the first 100 trading days, stocks have closed out the full year with an average return of about 25% .
This time last year , the S.P 500 was up over 8% and later closed the year with a gain of almost exactly 25% ,” a J.P. Morgan analyst says.
JPMorgan analyst Brian Cheng is bullish on Kyverna Therapeutics , a biopharmaceutical company with an autoimmune focus.
Structure Therapeutics is a clinical-stage global biopharmaceutical company dedicated to discovering and developing new orally dosed therapeutic agents for chronic metabolic and pulmonary diseases.
The leading drug candidate in Structure ’s pipeline is GSBR-1290 , a selective GLP-1R agonist targets obesity and has completed a Phase 2a study.
VR Score
75
Informative language
71
Neutral language
52
Article tone
formal
Language
English
Language complexity
49
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
medium-lived
External references
6
Source diversity
1
Affiliate links
no affiliate links